Kymera Therapeutics is celebrating the signing of two partnerships, with Gilead Sciences taking an option on one molecular ...

Sanofi’s SNY stock has been trading below its 200-day and 50-day moving averages since early June. On June 23, the stock’s ...

The ADDF’s CFO discusses the areas that foundation is raising money for and how its reacting to the current economic ...

Blueprint Medicines Corporation (NASDAQ: BPMC) is one of the best biotech stocks to invest in now. On June 12, Blueprint ...

Kymera Therapeutics sweetened news of a setback Wednesday, revealing that Sanofi is pulling back from its lead IRAK4 degrader ...

WATERTOWN, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines ...

Formation Bio’s subsidiary, Libertas Bio, has licensed gusacitinib, an oral dual JAK/SYK inhibitor, to Sanofi.

Sanofi said this morning that its pipeline includes 12 potential blockbuster drugs ... we are making decisive choices to deliver breakthrough medicines and long-term value for all of our ...

Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations ...

The National Academy of Sciences, Engineering, and Medicine will convene an ad hoc committee to develop a blueprint, including specific, actionable steps for building and sustaining an infrastructure ...